Compare IDEXX Laboratories, Inc. (IDXX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Toronto-Dominion Bank — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Toronto-Dominion Bank trades at $115.1 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 4.6× IDEXX Laboratories, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.84% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Toronto-Dominion Bank for 84 Days on average.
| IDXX | TD | |
|---|---|---|
Market Cap | $40.43B | $185.79B |
Volume | 692,164 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $766.68 | $124.80 |
52-Week Low | $504.70 | $78.32 |
Typical Hold Time | 46 Days | 84 Days |
Enterprise Value | $41.32B | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
TD trades at $114.04, up 0.15% on the day, with a bearish technical signal but strong fundamentals including a 24.88% net income margin and three consecutive quarterly earnings beats. The company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30) and a $108 billion commitment to Canadian infrastructure (WSJ, 2026-09-14), signaling financial strength and strategic growth initiatives.
The outlook is mixed; robust profitability and shareholder returns via buybacks and dividends present opportunities, but volatile cash flows, high debt levels, and a bearish technical trend pose risks. Analyst consensus is positive with 53% buy ratings, though the stock faces headwinds from economic uncertainty and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
